Report

This MMWR report describes results of the Massachusetts Department of Public Health surveillance initiative to collect detailed information on hepatitis C virus (HCV) cases reported during 2007-2009 among 15-24-year olds, and to examine the data for trends through 2009. The results reveal the continued increase in rates of newly reported HCV infection among this age group. Cases were reported from all areas of the state, occurred predominantly among non-Hispanic white persons, and were equally distributed among male and females.

This report summarizes results of an investigation in which HCV was transmitted when a transplant facility mistakenly used a blood vessel conduit from an HCV-seropositive donor in a seronegative recipient in May 2009. In November of 2009, a second transplant facility identified two cases of potential hepatitis transmission from vessel conduits.

This report discusses the investigation of a hepatitis B virus (HBV) outbreak in an assisted living facility. The outbreak occurred because of the staff’s use of unsafe practices, including sharing reusable fingerstick lancing devices approved for single patient use only, and shared use of blood glucose meters without cleaning and disinfection between patients.

This article reports on a matched case-control study and viral analysis that examined the role of sexual transmission of Hepatics C virus (HCV) among HIV-infected men who have sex with men. In all, 22 case-patients and 53 control subjects were enrolled in the study. Participants completed self-administered questionnaires regarding sexual practices and drug-use behaviors during the 12 months preceding diagnosis or preceding the questionnaire.

This report summarizes trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000--2010 using data from the Gonococcal Isolate Surveillance Project (GISP). During that period, the percentage of isolates with elevated minimum inhibitory concentrations (MICs) to cephalosporins (=0.25 µg/mL for cefixime and =0.125 µg/mL for ceftriaxone) increased from 0.2% in 2000 to 1.4% in 2010 for cefixime and from 0.1% in 2000 to 0.3% in 2010 for ceftriaxone.

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years.

This report presents estimated numbers of HIV and AIDS diagnoses from the 42 areas (37 states and five US dependent areas) with confidential name-based HIV infection reporting since at least 2005. It also includes the statistics reported to CDC through 2008. The data presented in this report are subject to at least four limitations. First, HIV infection diagnoses might reflect both HIV incidence and testing patterns. Second, data were unavailable from certain states.

This report provides a short history of the discovery of HIV/AIDS and the present epidemiology and US National HIV/AIDS strategy.

This report summarizes results of CDC’s analysis of data from the National HIV Surveillance System on the 30th anniversary of the HIV/AIDS epidemic. The report characterizes trends in HIV infection and AIDS in the United States during 1981-2008. Results indicate that in the first 14 years, sharp increases were reported in the number of new AIDS diagnoses and deaths reaching highs of 75,457 in 1992 and 50,628 in 1995. However with the introduction of highly active antiretroviral therapy, AIDS diagnoses and deaths declined substantially from 1995-1998, and remained stable from 1999-2008.